📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
25 announcements match the current filters (relevance ≥ 5).
Sudeep Pharma Q2FY26 Update: FY25 Revenue at ₹502 Cr with 39.7% EBITDA Margin
Sudeep Pharma, which listed on BSE/NSE in November 2025, reported robust FY25 financials with a PAT of ₹139 crore and a high ROE of 28.1%. The company is undergoing a major capacity expansion, adding 51,200 MT to its existing 72,246 MT capacity, with commissioning expected by Q4FY26. It maintains a strong global presence across 100 countries, serving 1,100+ customers including 14 Fortune 500 companies. Additionally, the company is diversifying into high-growth battery materials, specifically iron phosphate for LFP batteries.
Key Highlights
FY25 Revenue of ₹502 Cr with a strong EBITDA margin of 39.7% and PAT margin of 27.6%.
Total manufacturing capacity to reach 1,23,446 MT following the commissioning of a new facility in Q4FY26.
High customer stickiness with 83.17% repeat business and an average 7-year relationship with top 5 customers.
Diversified revenue stream with 60% from Specialty Ingredients and 40% from Pharma, Food & Nutrition in H1FY26.
Strategic entry into sustainable battery materials through subsidiary Sudeep Advanced Materials (SAMPL).
👀 What to Watch
Investors should track the timely commissioning of the new Nandesari facility in Q4FY26, which will increase capacity by approximately 70%. The company's entry into the EV battery material supply chain provides a significant long-term growth catalyst beyond its core pharma excipients business.
Sudeep Pharma Q2 PAT Stable at ₹29.7 Cr; H1 Net Profit Jumps 31% YoY to ₹54.9 Cr
Sudeep Pharma reported a mixed set of results for Q2 FY26, with revenue from operations declining 17.3% YoY to ₹87.88 crore, while net profit remained stable at ₹29.74 crore. For the first half of the year (H1 FY26), the company achieved a significant 31% growth in net profit to ₹54.95 crore, largely supported by a substantial increase in other income. Operating cash flows showed a strong improvement, rising to ₹63.65 crore from ₹24.46 crore in the previous year. Additionally, the company strengthened its balance sheet by raising ₹160 crore through the issuance of compulsorily convertible preference shares.
Key Highlights
H1 FY26 Net Profit increased 31% YoY to ₹5,494.63 lakhs compared to ₹4,198.09 lakhs in H1 FY25.
Q2 FY26 Revenue from operations fell 17.3% YoY to ₹8,788.16 lakhs from ₹10,629.58 lakhs.
Other income for H1 FY26 surged to ₹1,944.70 lakhs from ₹298.97 lakhs in the previous year's period.
Net cash generated from operating activities improved significantly to ₹6,365.07 lakhs in H1 FY26.
The company raised ₹16,000 lakhs through the issuance of compulsorily convertible preference shares during the period.
👀 What to Watch
Investors should monitor the sustainability of the 'Other Income' which significantly boosted the bottom line despite a dip in quarterly revenue. The strong improvement in operating cash flow and successful fundraise are positive indicators for the company's liquidity and expansion plans.
Sudeep Pharma Q2 PAT Up 18% QoQ to ₹29.74 Cr; H1 PAT Surges 31% YoY
Sudeep Pharma reported a standalone Profit After Tax (PAT) of ₹29.74 crore for Q2 FY26, marking an 18% sequential growth. While quarterly revenue from operations declined 17.3% YoY to ₹87.88 crore, the bottom line was significantly bolstered by other income, which rose to ₹12.83 crore. For the first half of FY26, PAT grew by 30.9% YoY to ₹54.95 crore despite flat revenue growth. The company also demonstrated strong liquidity management, with operating cash flows increasing to ₹63.65 crore.
Key Highlights
Q2 FY26 PAT rose 18% QoQ to ₹29.74 crore, supported by a sharp rise in other income to ₹12.83 crore.
H1 FY26 PAT grew 30.9% YoY to ₹54.95 crore, even as H1 revenue remained flat at ₹168.06 crore.
Operating cash flow improved significantly to ₹63.65 crore in H1 FY26 compared to ₹24.46 crore in H1 FY25.
Company raised ₹160 crore via Compulsorily Convertible Preference Shares (CCPS) during the period.
Loans extended to subsidiaries amounted to ₹174.48 crore, indicating significant intra-group capital deployment.
👀 What to Watch
Investors should monitor the sustainability of 'Other Income' which heavily supported profits this quarter despite a YoY revenue dip. The strong cash flow and successful fundraise via CCPS provide a solid cushion for the company's expansion plans.
SUDEEPPHRM Announces Earnings Call on December 22, 2025
Sudeep Pharma Limited has scheduled an earnings call with analysts and investors on December 22, 2025, at 11:30 a.m. IST. The purpose of the call is to discuss the operational and financial performance for the quarter and half year ended on September 30, 2025. Investors can access the call through the provided registration link. Contact information for ICICI Securities representatives is provided for any clarifications.
Key Highlights
Earnings call scheduled for December 22, 2025 at 11:30 a.m. IST
Call to discuss financial performance for the quarter and half year ended September 30, 2025
Company Secretary is Dimple Mehta, M. No.: F13184
👀 What to Watch
Investors interested in Sudeep Pharma's performance should attend the earnings call on December 22, 2025, to gain insights into the company's financial results and future outlook. Review the company's website for additional information.
Sudeep Pharma Grants INR 40 Cr Loan to Subsidiary for Battery Material Expansion
Sudeep Pharma Limited has entered into a loan agreement to provide an unsecured loan of INR 40 Crore to its wholly-owned subsidiary, Sudeep Advanced Materials Private Limited. The funds are specifically earmarked for working capital and the acquisition of industrial land in Dahej, Gujarat, to establish a commercial manufacturing facility for battery-grade precursor materials, primarily Iron Phosphate. The loan carries an interest rate of 8.5% per annum and is repayable on demand within a maximum period of five years. This move highlights the company's strategic push into the high-growth battery materials and EV supply chain sector.
Key Highlights
Loan amount of INR 40 Crore granted with an overall facility limit of INR 50 Crore
Funds to be used for land purchase and setting up a manufacturing facility for Iron Phosphate in Dahej
Unsecured loan carries an interest rate of 8.5% with a maximum tenure of 5 years
Current outstanding loan to the subsidiary as of the disclosure date is INR 9.25 Crore
Strategic focus on Battery Grade Precursor Materials indicates diversification into the energy storage value chain
👀 What to Watch
Investors should view this as a positive growth signal as the company expands into the specialized battery materials market. Monitor the execution timelines for the Dahej facility and future revenue contributions from this subsidiary.
